Next Step Realty

Canterbury Park Holding Corporation Reports 2023 Third Quarter Results

Retrieved on: 
Thursday, November 9, 2023
Steps, Sale, Minneapolis–Saint Paul, EBITDA, Food, Security (finance), Bank statement, Investment, Restaurant, Omri Sharon, Database, Depreciation, Insurance, Tax, Weather, Calendar, Marketing, GAAP, Adjustment, Table, Next Step Realty, Environment, Bank, Rare-earth element, Bookkeeping, Tourism, Cryptocurrency

Non-GAAP financial measures are not intended to be considered in isolation from, a substitute for, or superior to GAAP results.

Key Points: 
  • Non-GAAP financial measures are not intended to be considered in isolation from, a substitute for, or superior to GAAP results.
  • “Canterbury Park’s third quarter results represent a continuation of solid Casino segment performance offset by higher operating costs and our previously disclosed reduced racing calendar compared to the year-ago period.
  • Swervo Development Corporation (“Swervo”) has begun full-scale development of its state-of-the-art amphitheater with significant activity underway on the 37-acre site.
  • Doran Properties Group continues its development of Phase II of the upscale Triple Crown Residences at Canterbury Park, with initial occupancy anticipated in January 2024.

Canterbury Park Holding Corporation Reports 2023 Second Quarter Results

Retrieved on: 
Thursday, August 10, 2023
Steps, Heart, Canterbury Park, Insurance, Table, Marketing, Bank statement, Omri Sharon, Greystone, COVID-19, Calendar, Tax, Foodservice, GAAP, Sale, Parimutuel betting, EBITDA, Next Step Realty, Investment, Restaurant, Cooperative, Depreciation, Growth, Security (finance), Adjustment, Bank, Tourism, Dairy, Agriculture, Life insurance, Cryptocurrency, Bookkeeping, Food

Second quarter net revenue of $16.3 million and adjusted EBITDA of $2.0 million resulted in adjusted EBITDA as a percentage of revenue of 12.4%.

Key Points: 
  • Second quarter net revenue of $16.3 million and adjusted EBITDA of $2.0 million resulted in adjusted EBITDA as a percentage of revenue of 12.4%.
  • Pari-mutuel revenue declined 31.8% year-over-year primarily due to a significant decline in out-of-state handle on Canterbury Park races.
  • During the second quarter of 2023, we completed the $8.8 million sale of 37 acres of land to Swervo Development Corporation (“Swervo”) which cleared the way for it to begin development of a state-of-the-art amphitheater.
  • Further financial information for the second quarter ended June 30, 2023 is presented in the accompanying tables at the end of this press release.

Canterbury Park Holding Corporation Reports First Quarter Results

Retrieved on: 
Thursday, May 11, 2023
Steps, Insurance, Food, Table, Drink, George H. Doran Company, Bank statement, Omri Marcus, Greystone, COVID-19, Calendar, Tax, GAAP, Sale, EBITDA, Next Step Realty, Investment, Restaurant, Sport, Depreciation, Growth, Weather, Security (finance), Adjustment, Bar, Bank, Tourism, Dairy, Cryptocurrency, Bookkeeping, Swervo

Non-GAAP financial measures are not intended to be considered in isolation from, a substitute for, or superior to GAAP results.

Key Points: 
  • Non-GAAP financial measures are not intended to be considered in isolation from, a substitute for, or superior to GAAP results.
  • Doran Companies continues its development of Phase II of the upscale Triple Crown Residences at Canterbury Park, with occupancy for some of the units anticipated in January 2024.
  • Lifestyle Communities expects to begin construction of Artessa at Canterbury Park – a cooperative community featuring a 56-unit building with over 5,000 square feet of amenity spaces – in Fall 2023.
  • Adjusted EBITDA, a non-GAAP measure, decreased 30.0% year-over-year to $2.5 million in the 2023 first quarter, compared to $3.5 million in the 2022 first quarter.

Our research shows home working didn't harm mental health at the start of the pandemic – but things changed later on

Retrieved on: 
Thursday, May 11, 2023
Steps, Male, Generation Scotland, Employment, Area studies, Dunedin Multidisciplinary Health and Development Study, 1970 British Cohort Study, Research, Loneliness, COVID, National Child Development Study, Next Step Realty, CQD, Population, Time, Risk, Ageing, English Longitudinal Study of Ageing, Cohort study, Mental health, Female, Fatigue, Nursing, Pharmaceutical industry, Video game

According to UK data, almost 60% of people were working fully or partially from home between April and June 2020.

Key Points: 
  • According to UK data, almost 60% of people were working fully or partially from home between April and June 2020.
  • Between September 2022 and January 2023, 16% of working adults in the UK reported working fully from home, and 28% working partially from home.
  • My colleagues and I wanted to understand how home working correlated with mental health and social wellbeing during the pandemic.

Changes over time

    • Our findings show the relationship between home working and mental health changed over the course of the pandemic.
    • In both April-June and July-October 2020, we found no significant difference between those working from home and those working at their employer’s premises.
    • For example, it’s possible that during the first lockdown, working from home was novel for some people.

Some nuances

    • For example, female workers were at higher risk of psychological distress and low life satisfaction compared with male workers, independently of whether they worked from home or not.
    • This echoes other research which has shown women’s mental health deteriorated disproportionately at the height of the pandemic.

Limitations and where to next

    • We might expect that people who had previously worked from home may have been less directly affected by the pandemic shift to home working.
    • However, no information on pre-pandemic home working was available for six of the seven studies.
    • Notably, some people may be at greater risk – in particular, female workers and those without a higher education degree.

Canterbury Park Holding Corporation Reports 2022 Fourth Quarter Results

Retrieved on: 
Monday, March 20, 2023
Steps, Canterbury Park, Spring Education Group, Shakopee, Minnesota, Partnership, Food, CMA, Table, Bank statement, Omri Sharon, COVID-19, Tax, Income tax, American Rescue Plan Act of 2021, GAAP, Sale, EBITDA, Next Step Realty, Work, Investment, Restaurant, Financial result, Depreciation, Growth, Security (finance), Adjustment, Pulte, Environment, Cryptocurrency, Bank, Tourism, Bookkeeping, Airline

Results for the three month periods ended December 31, 2022 and December 31, 2021 and the twelve months ended December 31, 2022 reflected no closures or capacity limitations.

Key Points: 
  • Results for the three month periods ended December 31, 2022 and December 31, 2021 and the twelve months ended December 31, 2022 reflected no closures or capacity limitations.
  • “Canterbury Park finished 2022 with strong fourth quarter financial results that continue to demonstrate the revenue, Adjusted EBITDA and margin growth profile we have established compared to pre-pandemic periods.
  • “Progress on the development of Canterbury Commons™ continued in the 2022 fourth quarter and in the first months of 2023.
  • Further financial information for the fourth quarter and full year ended December 31, 2022 is presented in the accompanying tables at the end of this press release.

AMPE Class Action Alert: If you Lost Money In Ampio Ampio Pharmaceuticals, Inc. (AMPE) Contact Robbins LLP for Information About Your Rights

Retrieved on: 
Friday, September 23, 2022
Steps, Securities Exchange Act of 1934, Knee, OAK, NYSE, Food, Efficacy, Company, Osteoarthritis, Next Step Realty, Person, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, U.S. Securities and Exchange Commission, Pain, SAN, GLOBE, Pharmaceutical industry

For more information regarding Ampio Pharmaceuticals, Inc.'s misconduct, click here .

Key Points: 
  • For more information regarding Ampio Pharmaceuticals, Inc.'s misconduct, click here .
  • Beginning in 2010 until approximately March 2022, Ampio conducted numerous clinical trials and analyses to determine Ampion's efficacy.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • You do not have to participate in the case to be eligible for a recovery.

Ampio Pharmaceuticals, Inc. Stockholder Notice: Have you lost money in Ampio Pharmaceuticals? If so, contact Robbins LLP for information about your rights

Retrieved on: 
Saturday, September 17, 2022
Steps, Securities Exchange Act of 1934, Knee, OAK, NYSE, Food, Efficacy, Company, Osteoarthritis, Next Step Realty, Person, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, U.S. Securities and Exchange Commission, Pain, SAN, GLOBE, Pharmaceutical industry

For more information regarding Ampio Pharmaceuticals, Inc.'s misconduct, click here .

Key Points: 
  • For more information regarding Ampio Pharmaceuticals, Inc.'s misconduct, click here .
  • Beginning in 2010 until approximately March 2022, Ampio conducted numerous clinical trials and analyses to determine Ampion's efficacy.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • You do not have to participate in the case to be eligible for a recovery.

AMPE Equity Alert: Robbins LLP Reminds Ampio Pharmaceuticals, Inc. Shareholders with More Than $100,000 in Losses to Contact the Firm

Retrieved on: 
Monday, September 12, 2022
Steps, Securities Exchange Act of 1934, Knee, OAK, NYSE, Food, Efficacy, Company, Osteoarthritis, Next Step Realty, Person, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, U.S. Securities and Exchange Commission, Pain, Pharmaceutical industry

For more information regarding Ampio Pharmaceuticals, Inc.'s misconduct, click here .

Key Points: 
  • For more information regarding Ampio Pharmaceuticals, Inc.'s misconduct, click here .
  • Beginning in 2010 until approximately March 2022, Ampio conducted numerous clinical trials and analyses to determine Ampion's efficacy.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • You do not have to participate in the case to be eligible for a recovery.

Ampio Pharmaceuticals, Inc. Stockholder Notice: Shareholders with More Than $100,000 in Losses Should Contact Robbins LLP For Information About the Class Action Lawsuit Against Ampio Pharmaceuticals, Inc.

Retrieved on: 
Friday, August 26, 2022
Steps, Osteoarthritis, Securities Exchange Act of 1934, NYSE, Pain, Knee, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, SAN, OAK, Efficacy, Person, Food, U.S. Securities and Exchange Commission, Next Step Realty, GLOBE, Company, Pharmaceutical industry

For more information regarding Ampio Pharmaceuticals, Inc.'s misconduct, click here .

Key Points: 
  • For more information regarding Ampio Pharmaceuticals, Inc.'s misconduct, click here .
  • Beginning in 2010 until approximately March 2022, Ampio conducted numerous clinical trials and analyses to determine Ampion's efficacy.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • You do not have to participate in the case to be eligible for a recovery.

Ampio Pharmaceuticals, Inc. Stockholder Alert: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit Against Ampio Pharmaceuticals, Inc.

Retrieved on: 
Monday, August 22, 2022
Steps, Complaint, Osteoarthritis, Securities Exchange Act of 1934, NYSE, Pain, Knee, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, SAN, OAK, Efficacy, Person, Food, Court, U.S. Securities and Exchange Commission, Next Step Realty, GLOBE, Company, Advertising, Pharmaceutical industry

For more information regarding Ampio Pharmaceuticals, Inc.'s misconduct, click here .

Key Points: 
  • For more information regarding Ampio Pharmaceuticals, Inc.'s misconduct, click here .
  • Beginning in 2010 until approximately March 2022, Ampio conducted numerous clinical trials and analyses to determine Ampion's efficacy.
  • Despite confidentially advertising on numerous occasions that Ampion demonstrated statistically significant decrease in pain associated in symptomatic moderate-severe OAK, the Company failed to bring Ampion to market.
  • Any member of the Class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent Class member.